Long-term follow-up of nevirapine-treated patients in a single-centre cohort

HIV Medicine

Volumn 10, Issue 8, 2009, Pages 461-469

  Colafigli, Manuela ^a   Di Giambenedetto, S ^a   Bracciale, L ^a   Fanti, I ^a   Prosperi, M ^b   Cauda, R ^a   De Luca, A ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

Durability; Long term; Nevirapine; Toxicity

Indexed keywords

NEVIRAPINE; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERLACTATEMIA; LIPID BLOOD LEVEL; LIPODYSTROPHY; LIVER FAILURE; LIVER TOXICITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROBABILITY; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; TREATMENT DURATION; TREATMENT FAILURE; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD;

ADULT; ALANINE TRANSAMINASE; ANTI-RETROVIRAL AGENTS; ASPARTATE AMINOTRANSFERASES; CD4 LYMPHOCYTE COUNT; CHOLESTEROL, HDL; COHORT STUDIES; DRUG ERUPTIONS; DRUG THERAPY, COMBINATION; DRUG-INDUCED LIVER INJURY; FEMALE; HIV INFECTIONS; HUMANS; LIVER; MALE; MEDICATION ADHERENCE; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 68449085659     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2009.00713.x     Document Type: Review

References (24)

1. Merluzzi VJ, Hargrave KD, Labadia M et al. Inhibition of HIV-1 reverse transcriptase by a nonnucleoside reverse inhibitor. Science 1990; 250: 1411-1413.
2. Van Leth F, Phanuphak P, Ruxrungtham K et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: A randomised open-label trial, the 2NN Study. Lancet 2004; 363: 1253-1263.
3. Martinez E, Arnaiz JA, Podzamczer D et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003; 349: 1036-1046.
4. Lange Joep MA. Efficacy and durability of nevirapine in antiretroviral drug naïve patients. J AIDS 2003; 34: S40-S52.
5. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents [a working group of the Office of AIDS Research Advisory Council (OARAC)]. Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents. Available at: http://aidsinfo.nih.gov (accessed 28 October 2008).
6. Clumeck N, Pozniak A, Raffi F, European Aids Clinical Society (EACS) Executive Committee. Guidelines for the Clinical Management and Treatment of HIV Infected Adults in Europe 2007. Available at: http://www.eacs.eu (accessed 15 July 2008).
7. Murphy RL. Defining the toxicity profile of nevirapine and other antiretroviral drugs. J AIDS 2003; 34: S15-S20.
8. Martinez E, Blanco JL, Arnaiz JA et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001; 15: 1261-1268.
9. Sanne I, Mommeja-Marin H, Hinkle J et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. JID 2005; 191: 825-829.
10. Stern J, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL. A comprehensive safety analysis of nevirapine in different populations of HIV-infected patients. J AIDS 2003; 34: S21-S33.
11. Sloas Baylor M, Johann-Liang R. Hepatotoxicity associated with nevirapine use. J AIDS 2004; 35: 538-539.
12. Reliquet V, Allavena C, François-Brunet C et al. Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naïve HIV-infected patients: 3-year follow-up of the VIRGO Study. HIV Med 2006; 7: 431-436.
13. Shalit P, Farrel P, Lindgren P. Long term safety and efficacy of nevirapine, stavudine and lamivudine in a real world setting. AIDS 2001; 15: 804-805.
14. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283: 74-80.
15. Maggiolo F, Arici C, Airoldi M et al. Reasons for discontinuation of nevirapine-containing HAART: Results from an unselected population of a large clinical cohort. J Antimicrob Chemother 2007; 59: 569-572.
16. Knobel H, Guelar A, Montero M et al. Risk of side-effects associated with the use of nevirapine in treatment-naïve patients, with respect to gender and CD4 cell count. HIV Med 2008; 9: 14-18.
17. Gil P, De Górgolas M, Estrada V et al. Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV-1-infected patients with undetectable virus load. CID 2004; 39: 1024-1029.
18. Bonjoch A, Paredes R, Domingo P et al. Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients. AIDS Res Hum Retroviruses 2006; 22: 321-329.
19. Rivero A, Mira JA, Pineda JA. Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother 2007; 59: 342-346.
20. Martinez E, Blanco JL, Arnaiz JA et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001; 15: 1261-1268.
21. Aranzabal L, Casado JL, Moya J et al. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C coinfection. Clin Infect Dis 2005; 40: 588-593.
22. Philips E, Gutierrez S, Jahnke N et al. Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naïve HIV-positive patients. AIDS 2007; 21: 1561-1568.
23. Clotet B, Van der Valk M, Negredo E, Reiss P. Impact of nevirapine on lipid metabolism. J AIDS 2003; 34: S79-S84.
24. Martinez A, Arnaiz JA, Pozdamczer D et al. Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients. AIDS 2007; 21: 367-369.